(Q35573921)

8 August 2017

1 reference

title

Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis (English)

1 reference

primary biliary cholangitis

8 August 2017

0 references

0 references

1 reference

0 references

author name string

Cynthia Levy

1

1 reference

8 August 2017

Keith D. Lindor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14594136

27 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14594136

27 March 2024

publication date

1 November 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S1089326103000977?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00097-7

https://api.elsevier.com/content/article/PII:S1089326103000977?httpAccept=text/plain

27 March 2024

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00097-7

27 March 2024

published in

Clinics in liver disease

1 reference

8 August 2017

7

1 reference

8 August 2017

4

1 reference

8 August 2017

901-910

1 reference

Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years

8 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Bone disease in primary biliary cirrhosis: independent indicators and rate of progression.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Vitamin D-receptor genotypes as independent genetic predictors of decreased bone mineral density in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Osteoporosis and bone mineral metabolism disorders in cirrhotic patients referred for orthotopic liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Rates of cancellous bone remodeling and turnover in osteopenia associated with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Bone loss in primary biliary cirrhosis: absence of association with severity of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Sodium fluoride prevents bone loss in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Cyclical etidronate in the prevention of bone loss in corticosteroid-treated primary biliary cirrhosis. A prospective, controlled pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Randomized pilot trial of vitamin K2 for bone loss in patients with primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Calcitriol for bone loss in patients with primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Fat-soluble vitamin levels in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Fat-Soluble Vitamin Nutriture in primary Biliary Cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Impaired release of vitamin A from liver in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Effect of ursodeoxycholic acid on serum lipids of patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Effect of bezafibrate in primary biliary cirrhosis: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Is bezafibrate histologically effective for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2803%2900097-7

7 January 2021

Factors influencing the development of metabolic bone disease in primary biliary cirrhosis

7

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00097-7

Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference?

27 March 2024

14

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00097-7

Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment

27 March 2024

16

1 reference

https://api.crossref.org/works/10.1016/S1089-3261(03)00097-7

27 March 2024

Identifiers

1 reference

8 August 2017

1 reference